STAAR Surgical Co
STAA17.580USD
+0.510+2.99%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
867.64MMarket Cap
LossP/E TTM
More Details of STAAR Surgical Co Company
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
STAAR Surgical Co Info
Ticker SymbolSTAA
Company nameSTAAR Surgical Co
IPO dateFeb 24, 1992
CEOFarrell (Stephen C)
Number of employees1157
Security typeOrdinary Share
Fiscal year-endFeb 24
Address1911 Walker Ave
CityMONROVIA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code91016
Phone16263037902
Websitehttps://www.staar.com/
Ticker SymbolSTAA
IPO dateFeb 24, 1992
CEOFarrell (Stephen C)
Company Executives of STAAR Surgical Co
Name
Name/Position
Position
Shareholding
Change
Mr. Wei Jiang
Mr. Wei Jiang
Director
Director
67.50K
+20967.00%
Mr. Stephen C. (Steve) Farrell, CPA
Mr. Stephen C. (Steve) Farrell, CPA
Chief Executive Officer, Director
Chief Executive Officer, Director
35.16K
--
Mr. Warren Foust
Mr. Warren Foust
President, Chief Operating Officer
President, Chief Operating Officer
19.31K
--
Dr. Magda Michna, Ph.D.
Dr. Magda Michna, Ph.D.
Chief Development Officer
Chief Development Officer
9.76K
--
Ms. Deborah J. Andrews
Ms. Deborah J. Andrews
Chief Financial Officer
Chief Financial Officer
8.59K
+8586.00%
Mr. Nathaniel B. Sisitsky, Esq.
Mr. Nathaniel B. Sisitsky, Esq.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
8.19K
-2616.00%
Dr. Elizabeth Yeu, M.D.
Dr. Elizabeth Yeu, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
5.10K
+5099.00%
Mr. Louis E. (Lou) Silverman
Mr. Louis E. (Lou) Silverman
Independent Director
Independent Director
475.00
--
Mr. Brian Moore
Mr. Brian Moore
Vice President - Investor Relations and Corporate Development
Vice President - Investor Relations and Corporate Development
--
--
Ms. Lilian Zhou
Ms. Lilian Zhou
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Wei Jiang
Mr. Wei Jiang
Director
Director
67.50K
+20967.00%
Mr. Stephen C. (Steve) Farrell, CPA
Mr. Stephen C. (Steve) Farrell, CPA
Chief Executive Officer, Director
Chief Executive Officer, Director
35.16K
--
Mr. Warren Foust
Mr. Warren Foust
President, Chief Operating Officer
President, Chief Operating Officer
19.31K
--
Dr. Magda Michna, Ph.D.
Dr. Magda Michna, Ph.D.
Chief Development Officer
Chief Development Officer
9.76K
--
Ms. Deborah J. Andrews
Ms. Deborah J. Andrews
Chief Financial Officer
Chief Financial Officer
8.59K
+8586.00%
Mr. Nathaniel B. Sisitsky, Esq.
Mr. Nathaniel B. Sisitsky, Esq.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
8.19K
-2616.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
China
55.83M
58.94%
Others
22.04M
23.27%
Japan
11.23M
11.85%
U. S.
5.63M
5.95%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Broadwood Capital, Inc.
31.07%
BlackRock Institutional Trust Company, N.A.
13.23%
The Vanguard Group, Inc.
8.48%
Yunqi Capital Limited
6.55%
State Street Investment Management (US)
3.84%
Other
36.83%
Shareholders
Shareholders
Proportion
Broadwood Capital, Inc.
31.07%
BlackRock Institutional Trust Company, N.A.
13.23%
The Vanguard Group, Inc.
8.48%
Yunqi Capital Limited
6.55%
State Street Investment Management (US)
3.84%
Other
36.83%
Shareholder Types
Shareholders
Proportion
Hedge Fund
50.06%
Investment Advisor
34.51%
Investment Advisor/Hedge Fund
18.49%
Research Firm
2.92%
Pension Fund
1.14%
Individual Investor
0.53%
Bank and Trust
0.34%
Insurance Company
0.04%
Sovereign Wealth Fund
0.03%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
534
52.84M
106.24%
-14.23M
2025Q3
511
49.83M
100.45%
-14.96M
2025Q2
543
53.99M
109.59%
-5.64M
2025Q1
586
53.67M
108.47%
-5.73M
2024Q4
611
49.68M
100.75%
-8.34M
2024Q3
633
50.35M
102.36%
-6.37M
2024Q2
636
49.69M
101.15%
-10.70M
2024Q1
632
50.54M
103.45%
-9.24M
2023Q4
640
52.70M
107.96%
-9.84M
2023Q3
658
55.47M
114.38%
-3.16M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Broadwood Capital, Inc.
15.02M
30.19%
--
--
Dec 15, 2025
BlackRock Institutional Trust Company, N.A.
6.58M
13.23%
-133.07K
-1.98%
Sep 30, 2025
The Vanguard Group, Inc.
4.26M
8.56%
-121.64K
-2.78%
Sep 30, 2025
Yunqi Capital Limited
2.50M
5.03%
--
--
Dec 10, 2025
State Street Investment Management (US)
1.91M
3.84%
-91.94K
-4.59%
Sep 30, 2025
Balyasny Asset Management LP
1.81M
3.65%
+1.81M
--
Sep 30, 2025
Magnetar Capital Partners LP
1.20M
2.42%
+1.20M
--
Sep 30, 2025
Geode Capital Management, L.L.C.
1.17M
2.36%
-19.00K
-1.59%
Sep 30, 2025
Goldman Sachs & Company, Inc.
863.00K
1.74%
+745.45K
+634.18%
Sep 30, 2025
Sand Grove Capital Management LLP
829.12K
1.67%
+829.12K
--
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AltShares Merger Arbitrage ETF
2.71%
ProShares Merger ETF
2.53%
State Street SPDR S&P Health Care Equipment ETF
1.67%
NYLI Merger Arbitrage ETF
0.87%
Invesco S&P SmallCap Health Care ETF
0.79%
Royce Quant Small-Cap Quality Value ETF
0.26%
State Street SPDR S&P SmallCap 600 ESG ETF
0.13%
iShares S&P Small-Cap 600 Growth ETF
0.1%
State Street SPDR S&P 600 Small Cap Growth ETF
0.1%
iShares ESG Select Screened S&P Small-Cap ETF
0.1%
View more
AltShares Merger Arbitrage ETF
Proportion2.71%
ProShares Merger ETF
Proportion2.53%
State Street SPDR S&P Health Care Equipment ETF
Proportion1.67%
NYLI Merger Arbitrage ETF
Proportion0.87%
Invesco S&P SmallCap Health Care ETF
Proportion0.79%
Royce Quant Small-Cap Quality Value ETF
Proportion0.26%
State Street SPDR S&P SmallCap 600 ESG ETF
Proportion0.13%
iShares S&P Small-Cap 600 Growth ETF
Proportion0.1%
State Street SPDR S&P 600 Small Cap Growth ETF
Proportion0.1%
iShares ESG Select Screened S&P Small-Cap ETF
Proportion0.1%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
